Printer Friendly

DR. JONAS SALK, ELIE WIESEL HIGHLIGHT DEDICATION OF RPR'S RESEARCH AND CORPORATE HEADQUARTERS; AIDS BENEFIT FEATURES BACHARACH, WARWICK, FLACK

DR. JONAS SALK, ELIE WIESEL HIGHLIGHT DEDICATION OF RPR'S RESEARCH AND CORPORATE HEADQUARTERS; AIDS BENEFIT FEATURES BACHARACH, WARWICK, FLACK
 Who: Dr. Jonas Salk, discoverer of the polio vaccine, leader in
 AIDS vaccine research. Elie Wiesel, 1986 Nobel Peace
 Prize-winning author and social commentator.
 What: Salk, scientific advisor to California-based Immune
 Response Corp., which in partnership with RPR, is
 pursuing an AIDS therapeutic vaccine; and Wiesel, an
 Auschwitz survivor and prize-winning author and social
 commentator, will address a gathering of international
 dignitaries at the dedication of RPR's new U.S.
 Headquarters for Administration and Research and
 Development.
 An AIDS Benefit Concert featuring Burt Bacharach, Dionne
 Warwick, Roberta Flack and comedienne Elayne Boosler,
 8 p.m., Mann Music Center, 52nd and Parkside,
 Philadelphia. Proceeds benefit the Family AIDS Clinics
 at St. Christopher's Hospital and Childrens' Hospital of
 Philadelphia.
 When: Friday, Sept. 25 -- Dedication, 11 a.m. to 12:30 p.m.;
 Concert, 8 p.m.
 Why: To mark the global pharmaceutical company's commitment to
 world health. Salk will receive the inaugural RPR World
 Health Award, which will be presented annually to a
 person who, through selfless determination, improves
 human health throughout the world. AIDS Benefit Concert
 underscores a company commitment to world health and
 social responsibility through corporate and personal
 action.
 Where: Dedication: 500 Arcola Rd., Upper Providence Township, Pa.
 Concert: Mann Music Center.
 Highlights:
 -- Keynote Address by Wiesel, 11 a.m.
 -- Presentation of World Health Award to Salk by RPR's Chief
 Executive Officer Rob Cawthorn
 -- Salk's comments on state of AIDS research, RPR joint venture,
 award acceptance
 -- AIDS Benefit Concert, 8 p.m., Mann Music Center
 -- Complete press kits, photos and media accommodations available.
 Rhone-Poulenc Rorer (NYSE: RPR) is a global pharmaceutical company dedicated to the discovery, development, marketing and manufacture of human pharmaceuticals. RPR reported sales of $3.8 billion in 1991 and plans to invest more than $500 million in research and development in 1992.
 CONTACT: Dan Kelly of Rhone-Poulenc Rorer Public Affairs, 215-454-8460.
 /delval/
 -0- 9/15/92
 (RPR) CO: Rhone-Poulenc Rorer ST: Pennsylvania IN: MTC SU:


MJ-LJ -- PH018 -- 9659 09/15/92 13:14 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 15, 1992
Words:348
Previous Article:FORD DIVISION REPORTS 10-DAY SALES
Next Article:ITT ELECTS ROBERT BOWMAN EVP AND CHIEF FINANCIAL OFFICER
Topics:


Related Articles
SALK, WIESEL HIGHLIGHT DEDICATION OF HEADQUARTERS FOR RHONE-POULENC RORER; BACHARACH, WARWICK, FLACK AND BOOSLER HEADLINE AIDS BENEFIT
YOUNG AIDS VICTIM'S SONG INSPIRES BENEFIT CONCERT FOR PEDIATRIC AIDS CLINICS
RHONE-POULENC RORER, IMMUNE RESPONSE CORPORATION ANNOUNCE A DEDICATED MANAGEMENT TEAM FOR JOINT VENTURE DEVELOPING SALK AIDS-IMMUNOTHERAPEUTIC
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMENCE ARBITRATION
RHONE-POULENC RORER FILES DEMAND FOR ARBITRATION IN ST. LOUIS, MISSOURI
Remune controversy articles.
Salk Institute Lights Up in Pink and Blue.
The Elie Wiesel Foundation for Humanity and LRN Announce Deadline Extension for 2009 Prize in Ethics and Additional Awards for Students.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters